We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

67 hedge funds and large institutions have $33.5M invested in Matinas BioPharma in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

15% more capital invested

Capital invested by funds: $29.2M → $33.5M (+$4.24M)

0% more funds holding

Funds holding: 67 → 67 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

0.13% less ownership

Funds ownership: 0.37% → 0.24% (-0.13%)

Holders
67
Holders Change
–
Holders Change %
0%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
21
Reduced
9
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIG
Sargent Investment Group
Maryland
+$907K
2
AWA
Arkadios Wealth Advisors
Georgia
+$905K
3
VF
Virtu Financial
New York
+$199K
4
CCM
Courage Capital Management
Tennessee
+$173K
5
Citadel Advisors
Citadel Advisors
Florida
+$160K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$8.89M
2
GCP
GSA Capital Partners
United Kingdom
-$812K
3
Victory Capital Management
Victory Capital Management
Texas
-$768K
4
Renaissance Technologies
Renaissance Technologies
New York
-$472K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$465K
Name Holding Trade Value Shares
Change 		Change in
Stake
IFG
26
Investors Financial Group
Minnesota
$104K +$30.2K +700 +78%
Charles Schwab
27
Charles Schwab
California
$102K – – –
TSS
28
Two Sigma Securities
New York
$94K +$62.5K +1,448 New
SCP
29
Sandhill Capital Partners
New York
$91K +$34.5K +800 +133%
Morgan Stanley
30
Morgan Stanley
New York
$71K +$1.85K +43 +4%
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$68K +$13.7K +318 +44%
TRCT
32
Tower Research Capital (TRC)
New York
$60K +$39.6K +919 New
JP Morgan Chase
33
JP Morgan Chase
New York
$59K -$1.25K -29 -3%
WG
34
Winton Group
United Kingdom
$41K -$17.3K -402 -39%
JMPWA
35
JP Morgan Private Wealth Advisors
California
$41K +$27.4K +634 New
Victory Capital Management
36
Victory Capital Management
Texas
$39K -$768K -17,807 -97%
MA
37
MONECO Advisors
Connecticut
$39K -$17.3K -400 -40%
CWM
38
CCG Wealth Management
California
$39K – – –
Osaic Holdings
39
Osaic Holdings
Arizona
$34K +$3.45K +80 +18%
IWC
40
Integrated Wealth Concepts
Massachusetts
$33K -$30.2K -700 -58%
LB
41
Leo Brokerage
Texas
$31K +$20.7K +480 New
DAS
42
Dynamic Advisor Solutions
Arizona
$30K +$2.16K +50 +12%
Wells Fargo
43
Wells Fargo
California
$26K +$14.4K +333 +546%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$25K – – –
NRS
45
Neville Rodie & Shaw
New York
$23K – – –
OIA
46
OneDigital Investment Advisors
Kansas
$23K +$863 +20 +6%
SBWIC
47
Schaper Benz & Wise Investment Counsel
Wisconsin
$19K – – –
PCM
48
Perkins Capital Management
Minnesota
$19K +$12.5K +290 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$17K +$5.44K +126 +88%
CG
50
Clarus Group
Texas
$16K – – –
1
2
3 4

MTNB Hedge Fund Activity: Q3 2021 in Review

67 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2021, worth a combined $33.5M — up 15% from $29.2M a quarter earlier.

Fund positioning in MTNB was balanced in Q3 2021: 13 funds opened new positions, 13 closed out, 21 added to existing stakes and 9 trimmed.

The largest buyer was Sargent Investment Group, adding an estimated $907K. The largest seller was Boxer Capital, exiting entirely with an estimated $8.89M sold.

  • 67 institutional investors held Matinas BioPharma (MTNB) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $33.5M of Matinas BioPharma stock for Q3 2021, up 15% quarter-over-quarter.
  • 13 funds opened new Matinas BioPharma positions in Q3 2021 and 13 closed out, a net change of 0 holders.
  • The largest Matinas BioPharma buyer in Q3 2021 was Sargent Investment Group, an estimated $907K added.
  • The largest Matinas BioPharma seller in Q3 2021 was Boxer Capital, an estimated $8.89M sold.

Based on aggregated 13F filings for Q3 2021.